 CytoDyn Inc announced positive preliminary results from the 20-patient-cohort who have completed the open-label portion of the Phase 2 trial for nonalcoholic steatohepatitis NASH. The Vancouver-based companys current Phase 2 NASH trial is designed to test in 90 patients whether leronlimab may inhibit the devastating liver fibrosis associated with NASH. 